Skip to main content

Table 1 History and clinical characteristics of the four patients: Patients 1 and 2 were the previously reported mutations, Patients 3 and 4 were the novel mutations

From: Screening for ELANE, HAX1 and GFI1 gene mutations in children with neutropenia and clinical characterization of two novel mutations in ELANE gene

 

Patient 1

Patient 2

Patient 3

Patient 4

Gender

Male

Male

Female

Female

Age at presentation

1 month

1.5 months

21 days

1.9 years

Infection

Diarrhea, Pseudomonas aeruginosa pneumonia, Candida infection

Peritonitis, sepsis, pneumonia, skin, and liver abscess

Umbilical cord infection, gum infection, Pseudomonas aeruginosa sepsis, pneumonia

Pneumonia, cellulitis, abscesses, diarrhea, and otitis media

Initial ANC (/cu mm)

42

180

300

150

Clinical diagnosis

Severe congenital neutropenia

Cyclic neutropenia

Severe congenital neutropenia

Cyclic neutropenia

Bone marrow examination

Maturation arrest at promyelocyte

Maturation arrest at promyelocyte

Maturation arrest at promyelocyte

Maturation arrest at myelocyte

GCSF dosage (mcg/kg/day)

10

10

5

5.7

Other treatment

Haploidentical stem cell transplantation

None

None

None

FU time (year)

15.7

13.1

6.1

8

Outcome

Alive

Alive

Alive

Alive

Genetic study ELANE

(NM_001972.4)

c.253G > A

p.Gly85Arg, exon 3

c.301G > A

p.Val101Met, exon 3

c.234_236delCGC

p.Ala79del, exon 3

c.589_590insAGGCCGGC

p.Val197GlufsTer18, exon 4

ACMG criteria

Previously reported mutation

Previously reported mutation

Likely pathogenic variant

(PM1, PM4, PM2, PVS1, BP4)

Pathogenic variant

(PVS1, PM2, PS2)

Parent(s)

Mother: normal

Mother and father: normal

ND

Mother and father: no mutation

  1. ACMG, American College of Medical Genetics and Genomics; ND, Not done